The rejection of the promise doctrine has brought Canada into line with other countries and been welcomed by pharmaceutical companies. It also raises questions such as how courts will determine the “subject matter of the invention” and how the enhanced disclosure requirement will be resolved
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
Google and Sonos patent war continues; CNIPA finishes first administrative patent trials; Oppo halts German sales after Nokia wins; Chugai settles Fresenius suit; Taylor Swift claims she never heard Playas Gon’ Play; AI can’t be inventor, says Federal Circuit